Publications by authors named "Brian Calimlim"

Claim this Profile
E
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.
Alan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, Eric L Simpson, Kim A Papp, Brian M Calimlim

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2).
Jonathan I Silverberg, Melinda Gooderham, Norito Katoh, Valeria Aoki, Andrew E Pink, Brian Calimlim

Dermatol Ther (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.
Eric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, Kilian Eyerich, Norito Katoh, Brian M Calimlim

Dermatol Ther (Heidelb)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis.
Jonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, Andrew E Pink, Diego Ruiz Dasilva, Brian Calimlim

Dermatol Ther (Heidelb)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.
Jacob P Thyssen, David Rosmarin, Antonio Costanzo, Richard Warren, Chia-Yu Chu, Brian Calimlim

Dermatology· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.
Nina Magnolo, Michael C Cameron, Mona Shahriari, Bob Geng, Brian M Calimlim

J Dermatolog Treat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).
Jonathan I Silverberg, Christopher G Bunick, H Chih-Ho Hong, Pedro Mendes-Bastos, Linda Stein Gold, Brian Calimlim

Br J Dermatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks.
Amy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, Lawrence F Eichenfield, Weily Soong, Brian M Calimlim

JAMA Dermatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry.
Jonathan I Silverberg, Brian M Calimlim, Ayman Grada, Christopher G Bunick, Melinda J Gooderham

J Dermatolog Treat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis.
April W Armstrong, H Chih-Ho Hong, Brian M Calimlim, Marric G Buessing, Marjorie M Crowell

Dermatol Ther (Heidelb)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis.
Andrew Blauvelt, Kilian Eyerich, Alan D Irvine, Marjolein de Bruin-Weller, Shawn G Kwatra, Brian M Calimlim

Dermatol Ther (Heidelb)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis®.
Jonathan I Silverberg, Marjolein de Bruin-Weller, Brian M Calimlim, Xiaofei Hu, Sarah A Ofori

Dermatitis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Jonathan I Silverberg, Melinda J Gooderham, Amy S Paller, Mette Deleuran, Christopher G Bunick, Brian M Calimlim

Am J Clin Dermatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Eric L Simpson, Vimal H Prajapati, Yael A Leshem, Raj Chovatiya, Marjolein S de Bruin-Weller, Brian M Calimlim

Dermatol Ther (Heidelb)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib.
Shawn G Kwatra, Marjolein De Bruin-Weller, Jonathan I Silverberg, Peter Lio, Mette Deleuran, Brian M Calimlim

Acta Derm Venereol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
Kilian Eyerich, Melinda J Gooderham, Juan Francisco Silvestre, Stephen P Shumack, Pedro Mendes-Bastos, Brian M Calimlim

J Eur Acad Dermatol Venereol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient preferences for atopic dermatitis treatments: a discrete choice experiment.
Shawn G Kwatra, Peter Lio, Stephan Weidinger, Brian Calimlim, Barry Ladizinski

J Dermatolog Treat· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
Emma Guttman-Yassky, Jonathan I Silverberg, Diamant Thaçi, Kim A Papp, Sonja Ständer, Brian M Calimlim

J Eur Acad Dermatol Venereol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis.
Jonathan I Silverberg, H Chih-Ho Hong, Brian M Calimlim, Wan-Ju Lee, Henrique D Teixeira

Dermatol Ther (Heidelb)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).
Jonathan I Silverberg, Yael A Leshem, Brian M Calimlim, Jeffrey McDonald, Leighann Litcher-Kelly

Curr Med Res Opin· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A patient-centred conceptual model of nocturnal scratch and its impact in atopic dermatitis: A mixed-methods study supporting the development of novel digital measurements.
Lucia Cesnakova, Keith Meadows, Stefan Avey, Judy Barrett, Brian Calimlim

Skin Health Dis· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.
Jonathan I Silverberg, Brenda Simpson, Katrina Abuabara, Emma Guttman-Yassky, Brian Calimlim

J Am Acad Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
Andrew Blauvelt, Barry Ladizinski, Vimal H Prajapati, Vivian Laquer, Alison Fischer, Brian M Calimlim

J Am Acad Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
Amy S Paller, Barry Ladizinski, Pedro Mendes-Bastos, Elaine Siegfried, Weily Soong, Brian M Calimlim

JAMA Dermatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
Emma Guttman-Yassky, Jonathan Bar, Camille Rothenberg-Lausell, Lawrence Eichenfield, Ayman Grada, Brian Calimlim

J Drugs Dermatol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis